Bornhorst Joshua A, Figdore Daniel, Campbell Michelle R, Pazdernik Vanessa K, Mielke Michelle M, Petersen Ronald C, Algeciras-Schimnich Alicia
Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester Minnesota, USA.
Department of Quantitative Health Sciences, Mayo Clinic Rochester Minnesota, USA.
Clin Chim Acta. 2022 Oct 1;535:153-156. doi: 10.1016/j.cca.2022.08.017. Epub 2022 Aug 27.
Neurofilament light chain (NfL) is an emerging biomarker of neurodegenerative disease progression. As plasma NfL increases with age, characterization of NfL concentrations in an age-stratified cognitively unimpaired population was assessed.
EDTA-plasma samples were measured using the Simoa® NF-light™ Advantage Kit assay. One-sided reference intervals were established from 1100 cognitive normal individuals (588 male, 512 female) aged 20 to 95 years. Of those, 927 samples were obtained from the Mayo Clinic Study of Aging cohort (age > 50 years), and the remainder (age < 50 years) were obtained from individuals without known neurological conditions. All samples were from individuals without known chronic kidney disease, stroke or myocardial infarction, and a body mass index < 30 kg/m.
The 97.5th percentile limits for the following age ranges (in years) were (pg/mL): 20 s: ≤8.4, 30 s: ≤11.4, 40 s: ≤15.4, 50 s: ≤20.8, 60 s: ≤28.0, 70 s: ≤37.9, 80+: ≤51.2. Sex had no significant effect on reference intervals. Observed NfL concentrations increased at a rate of 3.1 % per year of age.
Characterization of the rate of NfL concentration increase and decade-wide reference intervals from a neurologically well-characterized patient population will aid in interpretation of NfL during the clinical evaluation of a potential neurodegenerative disease.
神经丝轻链（NfL）是神经退行性疾病进展过程中一个新兴的生物标志物。由于血浆NfL水平随年龄增长而升高，因此对年龄分层的认知未受损人群中的NfL浓度特征进行了评估。
使用Simoa® NF-light™ Advantage试剂盒对乙二胺四乙酸（EDTA）血浆样本进行检测。从1100名年龄在20至95岁之间的认知正常个体（588名男性，512名女性）中建立单侧参考区间。其中，927份样本来自梅奥诊所衰老研究队列（年龄>50岁），其余样本（年龄<50岁）来自无已知神经疾病的个体。所有样本均来自无已知慢性肾病、中风或心肌梗死且体重指数<30kg/m²的个体。
以下年龄范围（岁）的第97.5百分位数限值为（pg/mL）：20多岁：≤8.4，30多岁：≤11.4，40多岁：≤15.4，50多岁：≤20.8，60多岁：≤28.0，70多岁：≤37.9，80岁及以上：≤51.2。性别对参考区间无显著影响。观察到的NfL浓度以每年3.1%的速度随年龄增长。
从神经特征明确的患者群体中确定NfL浓度增加率和十年期参考区间，将有助于在潜在神经退行性疾病的临床评估中解释NfL水平。
